Last week, I ended with a question that still lingers:
Why does healthcare have to be so complicated?
We finally have Lenacapavir (Yeztugo)—a twice-a-year injectable HIV prevention drug with over 99% effectiveness, FDA-approved, and Science’s Breakthrough of the Year.
And yet, most people who need it can’t access it.
Because the elephant in the room hasn’t moved.
Cost. Access. Equity.
At $14,000 per injection (yes, per injection), Lenacapavir is financially out of reach for most people without comprehensive insurance or special programs.
For most people who are uninsured, underinsured, or navigating stigma-fueled healthcare systems, it might as well not exist.
And that’s heartbreaking.
We talk a lot about numbers, approvals, and breakthroughs.
But while statistics are powerful, stories are what truly remind us who this is for.
Because I’ve seen firsthand what’s at stake:
The newlywed wife whose spouse is living with HIV
The young man navigating a world full of overwhelming information and social pressure to conform
The trans woman who was brave enough to walk into a clinic, only to be turned away or mistreated
They deserve options. They deserve protection. They deserve dignity.
So What Can We Do About this Elephant in the Room?
🌸 Reduce Cost Through Policy: Push for Lenacapavir to be included in national insurance plans, Medicaid formularies, and donor-funded prevention programs.
Governments and payers must negotiate better pricing to make this life-saving tool affordable, not just available on paper.
🌸 Expand Delivery Access: Advocate for long-acting PrEP to be available not just in specialty clinics, but in community health centers, mobile clinics, and pharmacies.
Access should not depend on zip code, income, or insurance status.
🌸 Invest in Awareness & Training: Many providers still don’t know about Lenacapavir. We need a coordinated push to educate all clinicians on long-acting PrEP.
Especially those serving high-risk populations, so no opportunity for prevention is missed.
🌸 Center Community-Led Solutions: The people most impacted by HIV should be leading the conversation.
That means supporting peer educators, community-based organizations, and lived-experience advocates in designing and delivering outreach.
What About Metagenomics?
You might be wondering, “Where does metagenomics fit into all this?”
Let me explain.
While metagenomics isn’t used to diagnose HIV itself, it offers something just as vital:
Imagine if we could:
Spot increases in STIs like gonorrhea and syphilis—often linked with HIV—early, using advanced testing.
Identify new areas (Hot spots) where infections are spreading quickly, faster than usual reporting methods.
Use this information to focus HIV prevention efforts, like giving Lenacapavir, to the communities that need it most.
Here, metagenomics shines beyond just being a diagnostic tool. It stands out as a way to target prevention, amplify equity, and respond with precision.
This is the future I believe in.
Here’s how you can help:
If you're a clinician: Learn about Lenacapavir. Start the conversations. Push your institutions, your communities to consider more access.
If you’re a policymaker or funder: Make access equitable. Don’t let cost kill potential.
❤️ If you're reading this and feeling moved: Share it. Talk about it. Ask your healthcare provider or local clinic what’s available.
🔁 Let’s keep the conversation going.
📩 Have you or someone you know faced barriers to accessing PrEP?
💬 What role do you think emerging technologies like metagenomics can play in public health equity?